COMP <GO>
NEPH vs ABBV // EV/EBITDA & P/E VALUATION
Nephros Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: NEPH 5
— ABBV 7
▲ EV/EBITDA & P/E VALUATION LEADER: NEPH
LAST: $3.27 (+3.16%) • MKT CAP: $35.5M
valuation
26.3x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NEPH VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NEPH | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 61.90% | 70.20% | -8.30 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 18.90% | 29.00% | -10.10 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 26.3x | 33.3x | -7.00 | NEPH | /valuation <GO> |
| Free Cash Flow Yield | 4.50% | 3.47% | +1.03 | NEPH | /fcf-yield <GO> |
| Operating Margin | 6.10% | 24.60% | -18.50 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 6.40% | 6.90% | -0.50 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 32.70% | 8.60% | +24.10 | NEPH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.33 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | NEPH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.7 | 65.1 | -28.42 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.0x | 113.1x | -88.10 | NEPH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $35.5M | $513.86B | -$513.82B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NEPH REV | ABBV REV | NEPH GROSS % | ABBV GROSS % | NEPH FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $18.8M | $61.16B | 61.9% | 70.2% | $1.6M | $17.82B |
| FY 2024 | $14.2M | $56.33B | 61.6% | 70.0% | -$547.0K | $17.83B |
| FY 2023 | $14.2M | $54.32B | — | — | $827.0K | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NEPH // BETA —
ABBV // BETA 1.15